One exception is alpha-fetoprotein which has been shown to be significantly associated with treatment outcome in patients undergoing a combination therapy with Sorafenib and chemoembolization [43], and is also a predictor of HCC recurrence following liver transplantation [44]. This evidence concerns the gene AFP and hepatocellular carcinoma.